Video
Dr. Bukavina and Dr. Psutka share take-homes from kidney cancer epidemiology paper
Author(s):
“We need to continue to push the field forward, and the way we do that is to evaluate the risk factors and to stratify patients based on their risk factors and their genetic components,” says Laura Bukavina, MD, MPH.
Video Player is loading.
In this video, Laura Bukavina, MD, MPH, and Sarah P. Psutka, MD, MS, discuss the take-home messages from the European Urology study, “Epidemiology of Renal Cell Carcinoma: 2022 Update.” Bukavina is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Psutka is an associate professor of urology at University of Washington Medical Center, Seattle.
Related Videos
Study findings highlight gender gaps in oncology authorship and citation
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
BLUES trial: Silicone stents may improve patient care
Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jared S. Winoker, MD, discusses real-world study of CVAC 2.0 for kidney stones
Jim Hu, MD, on urinary continence recovery across RARP techniques
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
Mohit Khera, MD, on the impact of penile prosthesis implant on mental health
Special Report: Tips for PCPs on evaluating prostate cancer risk
Related Content
